Northland Securities initiated coverage on shares of Beximco Pharmaceuticals (LON:BXP) in a research note published on Tuesday morning. The firm issued a buy rating on the stock.
Separately, Northland Capital Partners restated a corporate rating on shares of Beximco Pharmaceuticals in a report on Tuesday, January 30th.
Shares of BXP stock opened at GBX 59.50 ($0.84) on Tuesday. Beximco Pharmaceuticals has a 1-year low of GBX 50.38 ($0.71) and a 1-year high of GBX 71.75 ($1.01).
TRADEMARK VIOLATION NOTICE: “Beximco Pharmaceuticals (BXP) Coverage Initiated at Northland Securities” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/beximco-pharmaceuticals-bxp-coverage-initiated-at-northland-securities.html.
About Beximco Pharmaceuticals
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. It offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products.
Receive News & Ratings for Beximco Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.